Follow us on:

Advanced Oncotherapy Current EV significantly below cumulative investment to date (VIDEO)

Advanced Oncotherapy (LON:AVO) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joins DirectorsTalk.

Martin updates us on some of the recent developments at the company, explains why the share price is languishing, the demand for the project, shares his thoughts on the success of LIGHT and the company valuation.

Advanced Oncotherapy plc is a UK-based company focused on delivering a cost-effective proton-based radiotherapy solution called LIGHT. Based on ground-breaking technology developed and tested at world renowned CERN in Switzerland, the LIGHT system delivers an integrated proton radiotherapy system to treat cancer.

You might also enjoy reading Real Estate Credit Investments, Insights from Hardman & Co Analyst Mike Foster on Strategy and Resilience (VIDEO)

Find more news, interviews, share price & company profile here for:

Hardman & Co

Share this interview

Other Interviews

Pantheon International Primary platform + active management = value add (Analyst Interview) January 6, 2022
Bank North Major steps forward (Analyst Interview) December 22, 2021
Appreciate Group demonstrating great confidence in long term growth (Analyst Interview) December 14, 2021
Palace Capital good clarity in NAV and EPS over and above the market (Analyst Interview) December 9, 2021
Volta Finance Simple Simon Says (Analyst Interview) December 8, 2021
Real Estate Credit Investments, Why rising rates should not hurt RECI (Analyst Interview) November 29, 2021
ICG Enterprise Trust in personal pensions: do as the professionals do (Analyst Interview) October 22, 2021
Fidelity European Trust PLC Follow the Money (Analyst Interview) October 14, 2021
Fidelity China Special Situations China growth story + market-beating style (Analyst Interview) October 7, 2021
Oakley Capital Investments 35% EBITDA growth drives 26% NAV return (Analyst Interview) October 1, 2021

More News

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.